Long-acting injectable XXXX : efficacy and safety of the first long-acting atypical antipsychotic.

@entity1 @entity161 @entity158 @entity21 @entity1090
OBJECTIVE: The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable @entity1090 ) in @entity1 with @entity161 . METHOD: In a 12-week, multicenter, double-blind, randomized study, @entity1 received intramuscular injections every 2 weeks of placebo or long-acting @entity1090 (25 mg, 50 mg, or 75 mg). The primary measure of efficacy was the change in total score on the Positive and Negative Syndrome Scale. RESULTS: Of the 554 @entity1 who were enrolled, 400 entered the double-blind study, and 370 received at least one postbaseline assessment. Mean changes in score of -6.2, -8.5, and -7.4 on the Positive and Negative Syndrome Scale were seen at endpoint for the 25-, 50-, and 75-mg @entity1090 groups, respectively; all three change scores were significantly different from that seen with placebo (+2.6). Improvements in positive and negative symptoms were also significantly greater in @entity1 receiving @entity1090 . Long-acting @entity1090 was well tolerated. Adverse events related to @entity21 were spontaneously reported by 13% of @entity1 receiving placebo and 10% of @entity1 in the 25-mg @entity1090 group, with higher rates in the 50-mg and 75-mg groups. Severity of @entity21 was mild at baseline and throughout the trial in each treatment group. Mean weight changes were small in the 25-, 50-, and 75-mg @entity1090 groups (0.5 kg, 1.2 kg, and 1.9 kg, respectively). @entity158 was rated as low by the @entity1 , consistent with the investigators' @entity158 ratings. CONCLUSIONS: Long-acting injectable @entity1090 was efficacious and well tolerated and provides both clinicians and @entity1 with a new mode of treatment that can improve the outcome of long-term therapy.
